Tissuemed
Tissuemed is a medical device developer and manufacturer based in Leeds, UK.
![]() | |
Type | Private |
---|---|
Industry | Medical Devices |
Headquarters | Leeds, West Yorkshire, U.K. |
Products | TissuePatch product family of surgical sealant films |
Website | www.tissuemed.com |
The company was founded in 1985 and developed the first tissue heart valve (derived from pigs) to receive regulatory approval (CE mark) in Europe. This business was divested in 1999 [1] and the heart values are currently sold by Vascutek, a Terumo company under the Aspire brand.[2][3] Thereafter Tissuemed focused on the development of innovative tissue adhesives for internal surgical use, including a light activated tissue sealant to prevent blood loss during vascular anastomosis, the TissueBond system.[4][5]
More recently in 2007, Tissuemed launched TissuePatch, a range of surgical sealant films for the prevention of leaks during surgery, including thoracic, general and neurosurgery.[6][7]
These products incorporate a unique synthetic bioadhesive that forms a covalent bond with tissue proteins, enabling adhesion to internal organs and achieving a sealing effect. In June 2016, Tissuemed won approval from China’s FDA for its TissuePatch surgical sealant.[8]
The company was acquired by Becton Dickinson in 2021.[9]
References
- AorTech buys TissueMed's heart valve division. Elservier Business Intelligence, 1999. http://www.elsevierbi.com/deals/199910268
- Kumar, P; Athanasiou T; Mussa S; Wood AJ. (2003). "Ten year experience with Aspire (Tissuemed) porcine bioprosthesis: single centre experience". Cardiovascular Surgery. 11 (2): 131–7. doi:10.1016/s0967-2109(03)00011-5. PMID 12664048.
- Goldsmith, IR; Spyt TJ; Boehm M; Kendall S; Rosin MD. (2001). "Midterm evaluation of the Tissuemed (Aspire) porcine bioprosthesis: 493 patients, 506 bioprostheses". The Annals of Thoracic Surgery. 71 (5): 1471–6. doi:10.1016/s0003-4975(01)02397-9. PMID 11383785.
- Birch, JF; Mandley DJ; Williams SL; Worrall DR; Trotter PJ; Wilkinson F; Bell PR. (2000). "Methylene blue based protein solder for vascular anastomoses: an in vitro burst pressure study". Lasers in Surgery and Medicine. 26 (3): 323–9. doi:10.1002/(sici)1096-9101(2000)26:3<323::aid-lsm11>3.0.co;2-r. PMID 10738296. S2CID 35428707.
- US patent 6,239,190, "Enhancement of activation for biological tissue adhesives, bonding agents and sealants using "color change" chromophores", published 2001, assigned to Tissuemed Ltd
- Ferroli, P; Acerbi, F; Broggi, M; Schiariti, M; Albanese, E; Tringali, G; Franzini, A; Broggi, G (March–April 2013). "A novel impermeable adhesive membrane to reinforce dural closure: a preliminary retrospective study on 119 consecutive high-risk patients". World Neurosurgery. 79 (3–4): 551–7. doi:10.1016/j.wneu.2011.09.022. PMID 22120260.
- Schiariti M, Acerbi F, Broggi M, Tringali G, Raggi A, Broggi G, Ferroli P. Two alternative dural sealing techniques in posterior fossa surgery: (Polylactide-co-glycolide) self-adhesive resorbable membrane versus polyethylene glycol hydrogel. Surg Neurol Int. 2014 Dec 3;5:171. doi: 10.4103/2152-7806.146154.
- "Tissuemed wins China's OK for TissuePatch surgical sealant – MassDevice". www.massdevice.com. June 2016. Retrieved October 16, 2017.
- Wright, Greg (December 14, 2021). "Leeds based medical device manufacturer Tissuemed is acquired by US-based Becton Dickinson". Yorkshire Post. Retrieved August 25, 2022.